| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| 100g |
|
||
| Other Sizes |
| Targets |
The primary molecular target of 1-Aminoindan is alpha-synuclein (alpha-Syn), a neuronal protein that misfolds and aggregates in Parkinson's disease. The compound binds directly to alpha-Syn, promoting a neuroprotective "loop" conformation that attenuates the misfolding and aggregation of this protein. It contributes to the overall neuroprotective activity attributed to Rasagiline. It is also an irreversible inhibitor of monoamine oxidase B (MAO-B), which is the primary mechanism of the parent drug. The compound also has moderate affinity for the adenosine A2A receptor.
|
|---|---|
| ln Vitro |
In vitro, 1-Aminoindan (0.1-10 uM) directly binds to purified recombinant alpha-synuclein protein, as measured by surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC). The binding induces a conformational change in the protein, reducing its aggregation propensity. In neuroblastoma cell models (e.g., SH-SY5Y cells overexpressing alpha-Syn), treatment with 1-Aminoindan (1-100 uM) reduces the number of alpha-Syn aggregates and protects cells from toxicity induced by alpha-Syn or MPP+. It also inhibits MAO-B activity in vitro with an IC₅0 in the low micromolar range.
|
| ln Vivo |
The neuroprotective activity of 1-Aminoindan has been demonstrated in vivo. In a mouse model of Parkinson's disease induced by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), administration of 1-Aminoindan (5-20 mg/kg, IP, once daily for 7 days) prior to MPTP treatment significantly reduced the loss of dopaminergic neurons in the substantia nigra and preserved striatal dopamine levels compared to vehicle-treated controls. The compound is also an impurity of the drug Rasagiline; its levels in Rasagiline drug substance are controlled to less than 0.5% to ensure product quality.
|
| Enzyme Assay |
To study the binding of 1-Aminoindan to alpha-Synuclein, surface plasmon resonance (SPR) is performed. Recombinant human alpha-Synuclein is immobilized on a CM5 sensor chip. 1-Aminoindan (0.1-1000 uM) in PBS buffer (pH 7.4) is injected over the surface. The sensorgram is recorded, and the equilibrium dissociation constant (Kd) is calculated. To measure MAO-B inhibition, a fluorometric assay is used: human MAO-B is incubated with 1-Aminoindan (0.1-100 uM) and the fluorogenic substrate kynuramine at 37degC for 30 min. The production of 4-hydroxyquinoline is measured fluorometrically (λex=315 nm, λem=380 nm), and the IC₅0 is calculated.
|
| Cell Assay |
For cell-based neuroprotection studies, SH-SY5Y neuroblastoma cells or primary midbrain neurons are seeded in 96-well plates (1×10⁴ cells/well). The cells are treated with 1-Aminoindan (0.1-100 uM) for 2-4 h. The neurotoxin MPP+ (1-methyl-4-phenylpyridinium, 1-5 mM) is then added to induce dopaminergic cell death. After 48 h, cell viability is measured by MTT assay. For alpha-Synuclein aggregation studies, HEK293 cells stably expressing alpha-synuclein-GFP are used. 1-Aminoindan is added for 48 h, and the number of aggregates is quantified by high-content imaging.
|
| Animal Protocol |
The MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson's disease is used to evaluate in vivo activity. Male C57BL/6 mice (6-8 weeks old, 20-25 g, n=10/group) are administered MPTP (30 mg/kg, IP) once daily for 5 consecutive days. 1-Aminoindan (5-20 mg/kg, IP) is given 30 min before each MPTP injection. Control groups receive vehicle alone or MPTP only. Seven days after the last MPTP injection, the mice are euthanized. The striatum is dissected, and dopamine levels are measured by HPLC-ECD. The number of tyrosine hydroxylase (TH)-positive neurons in the substantia nigra is counted by immunohistochemistry. A reduction in MPTP-induced dopamine depletion and TH+ neuron loss indicates neuroprotection.
|
| ADME/Pharmacokinetics |
1-Aminoindan (MW 133.19, LogP ~1.5) is a small, lipophilic molecule that is rapidly absorbed from the gastrointestinal tract. In rats, following a single oral dose of Rasagiline (1 mg/kg), 1-Aminoindan reaches peak plasma concentrations (Cmax) within 1-2 hours. The plasma half-life of the metabolite is approximately 6-8 hours, which is longer than that of the parent drug (t½ ~1.5 h). It is not extensively protein-bound. The compound is primarily eliminated by renal excretion after glucuronidation. The compound is an analytical standard and is not intended for therapeutic administration.
|
| Toxicity/Toxicokinetics |
For 1-Aminoindan, hazard statements: H315 (Causes skin irritation), H319 (Causes serious eye irritation), H335 (May cause respiratory irritation). Signal word: Warning. Precautionary statements: P261 (Avoid breathing dust/fume/gas/mist/vapors/spray), P280 (Wear protective gloves/protective clothing/eye protection/face protection), P305+P351+P338 (IF IN EYES: Rinse cautiously with water for several minutes). Storage: at 2-8degC in a tightly sealed container, protected from light. For research use only, not for human consumption.
|
| References |
|
| Additional Infomation |
1-Aminoindan (1-Indanamine; CAS# 34698-41-4) is a research-grade active metabolite of the anti-Parkinson's drug Rasagiline. It is not an FDA-approved drug. It is used as an impurity reference standard for the quality control (QC) of Rasagiline drug substance and as a research tool for studying alpha-synuclein aggregation and neuroprotection in Parkinson's disease. For research use only, not for diagnostic or therapeutic applications.
|
| Molecular Formula |
C9H11N
|
|---|---|
| Molecular Weight |
133.19
|
| Exact Mass |
133.089
|
| CAS # |
34698-41-4
|
| PubChem CID |
123445
|
| Appearance |
Liquid（Density: 1.038 g/cm3）
|
| Hydrogen Bond Donor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
10
|
| Complexity |
122
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CC2=CC=CC=C2C1N
|
| InChi Key |
XJEVHMGJSYVQBQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C9H11N/c10-9-6-5-7-3-1-2-4-8(7)9/h1-4,9H,5-6,10H2
|
| Chemical Name |
2,3-dihydro-1H-inden-1-amine
|
| Synonyms |
1-Indanamine; 2,3-Dihydro-1H-inden-1-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.5081 mL | 37.5404 mL | 75.0807 mL | |
| 5 mM | 1.5016 mL | 7.5081 mL | 15.0161 mL | |
| 10 mM | 0.7508 mL | 3.7540 mL | 7.5081 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
